Other

Viventia Biotech Inc.

Immunimed Inc.

Pradip K Maiti

Michael D Dan

Howard A Kaplan

Alec Sehon

Carol Grad, Legal Representative

Masaru Takata

The present invention provides a polyclonal antibody composition prepared from eggs of hens immunized with virulent antigens offor use in the treatment and prevention ofinfections in subjects with Inflammatory Bowel Disease including Ulcerative colitis and Crohn's disease. Respective groups of hens are immunized with Toxin A or Toxin B ofor aspore preparation. The polyclonal antibodies are recovered from eggs pooled from the immunized hens and the resulting antibody-egg powder is administered orally in a therapeutically effective amount to individuals infected with or suspected of being infected with

Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease

A polyclonal antibody composition prepared from eggs of immunized hens is used to treatinfections. Respective groups of hens are immunized with Toxin A or Toxin B ofor aspore preparation. The polyclonal antibodies are recovered from eggs pooled from the immunized hens and the resulting powder is administered in a therapeutically effective amount to individuals infected with or suspected of being infected with

[object Object]

Herein, it is shown that strong specific anti-methanogen avian antibodies can be produced when chickens are immunized with an optimal dose of methane producing bacterial antigen (methanogen) formulated with an appropriate adjuvant. The antibodies can in turn be used to reduce methane gas production from an animal by administering an effective amount of the anti-methanogen antibodies to the animal, thereby reducing methane gas evolved by the animal compared to an untreated or mock treated control animal of similar age and condition.

Use of avian anti-methanogen antibodies for reduction of methane production

The present invention relates to monoclonal antibody H11 and antigen binding fragments that specifically bind to the antigen recognized by H11, the C-antigen. The C-antigen is found specifically on neoplastic cells and not on normal cells. Also disclosed are polynucleotide and polypeptide derivatives based on H11, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the H11 antibody is effective in diagnosing, localizing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell lung carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients may also be treated concurrently with the antibodies and traditional anti-neoplastic agents.

Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers

Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

A method for suppressing the capacity of a mammal to mount an immune response which would be caused by the administration of one or more biologically active foreign proteins, comprising the administration of an immunosuppressively effective amount of a tolerogen corresponding to said foreign protein or proteins, said administration being performed prior to the administration of said protein or proteins.

Growing community of inventors

Winnipeg, Canada

Pradip K Maiti